Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Trip… (NCT03901690) | Clinical Trial Compass
UnknownPhase 3
Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study
Nicaragua102 participantsStarted 2019-08-27
Plain-language summary
In order to determine the Efficacy of Betaglucin 0.2% in gel vs Imiquimod 5% cream in the treatment of 102 individuals older than 18 years with anogenital warts trials in two arms 51 with Betaglucin 0.2% and 51 with Imiquimod 5%.
Who can participate
Age range18 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Men and women aged 18 to 50 years with anogenital wart visible on physical examination and positive for HPV 6 and 11 by polymerase chain reaction (PCR) test with detection by agarose gel electrophoresis.
Exclusion Criteria:
* Pregnant women.
* Vaccinated against human papillomavirus (Gardasil, Gardasil 9 or Cervarix).
* Patients Immunosuppressed by drugs (Chemotherapy, Corticoids, use of antibiotics for more than 7 days and/or antituberculous treatment.)
* Molluscum contagiosum.
* Skin Appendages.
* Urethral prolapse.
* Botryoid sarcoma.
* Herpes type II.
* History of anogenital surgery in the last 4 weeks.
* Intake of natural products or immunomodulators.
* Patients who have received 5% imiquimod cream.
What they're measuring
1
Cure Rate
Timeframe: 3 months
Trial details
NCT IDNCT03901690
SponsorCentro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri